Eton Pharmaceuticals (NASDAQ:ETON) Secures New U.S. Patent for Proprietary Formulation of Hydrocortisone –

On November 7, 2024, Eton Pharmaceuticals, Inc. announced in a press release that it has been granted a new U.S. Patent by the United States Patent and Trademark Office (USPTO) for its proprietary formulation ET-400, a liquid hydrocortisone product. The patent, previously known as U.S. Patent Application No. 18/443,889 and now identified as U.S. Patent No. 12,133,914, is set to remain in effect until the year 2043.

This newly acquired patent encompasses a specific method for utilizing oral liquid formulations of hydrocortisone and is anticipated to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book following the product’s approval process. Eton Pharmaceuticals had previously received its initial patent (US 11,904,046) for ET-400 back in February 2024 and currently has another U.S. patent application pending that pertains to the same product.

A comprehensive version of the press release can be accessed as Exhibit 99.1 attached to the Current Report on Form 8-K submitted by the company.

In compliance with the filing requirements, Eton Pharmaceuticals furnished additional details under Item 9.01 of the report. This section comprised the disclosure of the press release dated on November 7, 2024, embedded as Exhibit 99.1 along with an Interactive Data File integrated within the Inline XBRL document.

As per the regulatory obligations dictated by the Securities Exchange Act of 1934, the report was duly authorized and signed on behalf of Eton Pharmaceuticals by James R. Gruber, the Chief Financial Officer and Secretary, on November 7, 2024.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Eton Pharmaceuticals’s 8K filing here.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.